ADMA Biologics Reports Strong Q1 Profitability, 70.5% Gross Margin, and Initiates $125M Share Repurchase
ADMA is trading near its 52-week low of $7.21 (5.4% above the low) on elevated volume (2.0× avg).
Summary
ADMA Biologics reported strong first-quarter 2026 results with a 68.5% increase in net income, significant gross margin expansion, and a positive swing in operating cash flow, alongside the initiation of a $125 million accelerated share repurchase.
Key Events · Earnings and Guidance · ADMA
-
Strong Q1 Financial Performance
Net income for the three months ended March 31, 2026, increased by 68.5% to $45.3 million, up from $26.9 million in the prior year period. Diluted EPS rose to $0.19 from $0.11.
-
Significant Gross Margin Expansion
Gross profit increased to $80.8 million, resulting in a gross margin of 70.5% for Q1 2026, a substantial improvement from 53.2% in Q1 2025, primarily due to favorable product mix and yield enhancement manufacturing processes.
-
Positive Operating Cash Flow Turnaround
Net cash provided by operating activities was $58.2 million in Q1 2026, a significant increase from net cash used in operating activities of $19.7 million in Q1 2025.
-
ASCENIV Sales Growth
ASCENIV sales grew by 27.7% to $97.5 million, offsetting a decrease in BIVIGAM sales due to competitive pressures.
Analysis · ADMA · Life Sciences
ADMA Biologics delivered a robust first quarter, showcasing significant financial improvements. Net income surged by 68.5% year-over-year, driven by a substantial increase in gross profit and a remarkable expansion in gross margin from 53.2% to 70.5%. The company also achieved a significant turnaround in operating cash flow, moving from a deficit to a strong positive. This strong performance was primarily fueled by a 27.7% growth in ASCENIV sales, despite competitive pressures impacting BIVIGAM sales. The company also initiated a $125 million accelerated share repurchase program, funded by its revolving credit facility, demonstrating a commitment to returning capital to shareholders. This positive financial report follows the recent FDA approval for ASCENIV's pediatric label expansion, further strengthening the product's market potential.
At the time of this filing, ADMA was trading at $7.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $7.21 to $23.98. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.